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ABSTRACT 
Controversy still exists regarding the role of cholinergic pathways 
in the regulation of the hypothalamic-pituitary-adrenal axis in man. 
We studied the effects of the administration of placebo, pyridostig- 
mine (PD; 120 mg, orally), and the combination of PD and pirenzepine 
(PZP; 100 mg, orally) on ACTH, cortisol, and GH secretion at 0730 and 
2230 h in seven normal males. PD induced a clear decrease in ACTH 
levels at both times of the day compared to treatment with placebo, 
producing higher suppression in the nocturnal period (34.4 2 5.8% us. 
21.8 t 10.7%). The combination PD and PZP prevented the inhibitory 
action of PD on ACTH secretion in the morning, but not in the evening, 
when ACTH values showed a decrease similar to that seen after giving 
PD alone (38.1 ? 5.6% us. 34.4 2 5.80/u, respectively). Cortisol values 
declined only when the association PD plus PZP was given in the 
evening. GH levels had a significant increase after PD administration 
in the morning (4.1 t 1.2 ng/mL) and in the evening (10.2 2 1.6 
ng/mL), confirming that cholinergic stimulation was taking place, 
whereas the addition of PZP to PD induced a significant attenuation 
of these responses. It is concluded that cholinergic pathways have a 
inhibitory role in ACTH secretion in man. Ml muscarinic receptors 
seem to be involved in the diurnal inhibition of PD, whereas our 
observations are consistent with the mediation of another type of 
cholinergic receptors as an explanation for the nocturnal effect of PD 
on ACTH secretion. PD did not alter the circadian variation in the 
hypothalamic-pituitary-adrenal axis, whereas the association of PD 
and PZP increased the differences between diurnal and nocturnal 
ACTH values, suggesting a modulatory effect of the cholinergic sys- 
tem on the circadian rhythm of ACTH secretion. (J Clin Endocrinol 
Metah 81: 2902-2907, 1996) 
S EVERAL LINES of experimental evidence suggest that the cholinergic system exerts a stimulatory influence on 
hypothalamic-pituitary-adrenal (HPA) function. In 1967, 
Naumenko (1) showed that administration of anticholines- 
terase drugs to experimental animals was followed by an 
increase in glucocorticoid levels. Subsequent studies gave 
more support to the stimulatory role played by cholinergic 
pathways by demonstrating that implantation of atropine in 
the hypothalamic paraventricular nucleus inhibited the 
ACTH response to surgical stress (2). Other studies con- 
firmed that acetylcholine or its agonists are able to stimulate 
hypothalamic CRH secretion, an effect that can be blocked by 
muscarinic and nicotinic antagonists, suggesting the involve- 
ment of both types of cholinergic receptors (3,4). According 
to this, Calogero et al. (5) showed that either atropine or CRH 
antiserum administration prevented the stimulating effect of 
the muscarinic agonist arecoline on ACTH and corticoste- 
rone secretion in rats, providing further information about 
the preferential involvement of muscarinic receptors in the 
cholinergic modulation of the HPA axis. 
However, evidence of the role of cholinergic pathways in 
Received November 16, 1995. Revision received February 29, 1996. 
Accepted March 8, 1996. 
Address all correspondence and requests for reprints to: Dr. Javier 
Salvador, Department of Endocrinology, University Clinic of Navarra, 
31080 I’amplona, Spain. 
* This work was supported by grants from Fondo de Investigaciones 
Sanitarias de la S. Social (9310478) and Echebano Foundation 
(93-941308). 
the control of the HPA system in humans is scanty and 
controversial. Risch et al. (6, 7) reported a stimulatory effect 
of the cholinergic agonist physostigmine on ACTH, p-en- 
dorphin, and cortisol levels when given to normal subjects. 
Conversely, other researchers failed to show any influence of 
pyridostigmine administration on basal ACTH or cortisol 
levels in normal subjects (8,9). Also, Raskind et al. (10) found 
no changes in p-endorphin or cortisol levels in normal young 
individuals treated with physostigmine, in contrast to el- 
derly people who exhibited a stimulatory response. Recently, 
Murialdo et al. (11) demonstrated that pyridostigmine in- 
creases the pituitary-adrenal response to CRH in normal 
subjects, but not in patients with dementia. 
The relationships between cholinergic pathways and the 
HPA axis are of interest because of the participation of both 
hormonal systems in stress activation and behavior control 
(12,13). Our aim was to investigate the modulatory influence 
of cholinergic tone on spontaneous HPA activity and its 
circadian variation by looking at the changes in ACTH and 
cortisol secretion induced by administration of the anticho- 
linesterase agent pyridostigmine and the muscarinic antag- 
onist pirenzepine to a group of normal men in the morning 
and the evening. GH levels were also measured to ensure 
that effective cholinergic manipulation was taking place. 
Subjects 
Subjects and Methods 
Seven healthy male volunteers, aged 27-38 yr (mean, 29.7 t- 1.42 yr), 
were studied. All subjects were nonsmokers and had a normal physical 
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examination and a bodv mass index within the normal range (24.5 + 0.66 
kg/m’). Screening test results, including complete blood counts and 
standard biochemical urofile, were normal. All of the subjects had been 
free of any medical treatment for at least 3 months before starting the 
study. Subjects were submitted to the Hamilton test to rule out depres- 
sion. Informed consent for the study was obtained in all cases, and the 
protocol was approved by the local ethical committee. 
Methods 
Study design. All tests were performed in the clinical research unit. 
Subjects were fasted from 2200 h the night before each test. At 0730 h, 
an iv catheter was placed in an antecubital vein, which was kept patent 
by slow 0.9% saline infusion, Blood samples were taken every 15 min 
from 0800-1030 h for ACTH, cortisol, and GH estimations. At 0730 h, 
placebo, pyridostigmine (I’D; 120 mg; Mestinon, Roche, Madrid, Spain), 
or a combination of I’D (120 mg) and pirenzepine (PZP; 100 mg; Gas- 
trozepin, Boehringer Ingelheim, Barcelona, Spain) were given orally in 
random order on different days. All tests were repeated in the evening 
in each subject; drugs were administered at 2230 h, and blood samples 
were taken from 2300-0100 h. Tests were separated by at least 4 days. 
Subjects were not allowed to sleep during the tests and remained in the 
recumbent uosition until the end of the studv. Blood samples for ACTH I i 
were collected in prechilled tubes containing ethylenediamine tetraac- 
etate, placed immediately on ice, cold-centrifuged within 30 min, and 
stored at -70 C until assayed. 
Hormone nssays. ACTH was measured by immunoradiometric assay 
(Nichols Institute, San Juan Capistrano, CA). The sensitivity of the assay 
was 1 pg/mL. Inter- and intraassay coefficients of variation were 3% and 
3.2%, and 7.8% and 6.8%, respectively, for ACTH concentrations of 7.8 
and 81 pmol/L. Cortisol levels were estimated by RIA (Serono Diag- 
nostics, Chavannes-de-Bogis, Switzerland). The sensitivity of the assay 
was 7.4 nmol/L. Intra- and interassay coefficients of variation were 
4.05% and 4.64%, respectively. GH was measured by immunoradio- 
metric assay (Biomerieux, Marcy-L’Etoile, France). The sensitivity of the 
assay was 0.2 ng/mL. Intra- and interassay coefficients of variation were 
between 2-2.2% and between 3.7-6%, respectively, for GH concentra- 
tions ranging from 2.1-80.2 ng/mL. 
Dnta analysis. Integrated secretion corresponding to different time in- 
tervals (initial. 0800-0830 h and 2300-2330 h; middle, 0830-0930 h and 
2330-Ob30 h;‘final, 0930-1030 h and 0030-0130 h) as well as the area 
under the curve (AUC) of the full sampling period (total AUC, 0800- 
1030 h and 2300-0130 h) of ACTH, cortisol, and GH were calculated by 
trapezoidal solution to compare the results obtained under each con- 
dition The percent variation in integrated hormonal secretion after the 
administration of cholinergic drugs with respect to that observed after 
placebo treatment was estimated. Quantitative assessment of ACTH and 
cortisol circadian rhythms was calculated by measuring the percent 
reduction of integrated nocturnal values compared to morning levels. 
Statistical analysis was carried out by Wilcoxon’s rank sum test. Data are 
presented as the mean ? SEM. 
Results 
All subjects had mild transient abdominal pain after I’D 
administration when given alone or in combination with 
PZP. PZP caused transient dry mouth in all individuals. In 
no case were tests stopped or medications given. 
ACTH 
In the morning, ACTH levels remained stable following 
placebo administration. Maximum values were attained at 
0800 h (7.49 -C 1.09 pmol/L), declining slowly thereafter and 
reaching a nadir at 0915 h (4.50 i 0.7 pmol/L) to rise pro- 
gressively until the end of the sampling period (Fig. 1). As 
expected, nocturnal ACTH levels after placebo treatment 
were significantly lower, as assessed by total AUC values 
(Table l), according to a normal circadian variation. Thus, 
integrated ACTH secretion decreased to 45.5 5 4.8% with 
reference to morning values when placebo was given. 
Pretreatment with PD led to a significant decrease in 
ACTH levels (Fig. 1) and total AUC values (Table 1) in the 
morning as well as in the evening period compared with 
respective values after placebo treatment. The percent re- 
duction in total AUC values for ACTH in the evening was 
higher than that estimated in the morning test (34.4 2 5.8% 
us. 21.8 +- 10.7%). Although the inhibitory action of I’D on 
ACTH secretion became evident from the beginning and was 
uniform over the duration of the evening test, during the 
morning the effect took place mainly in the final phase of the 
sampling period (Fig. 1). PD administration did not change 
the circadian pattern of ACTH, as assessed by estimation of 
the percent variation in integrated ACTH secretion between 
morning and evening values (53.6 -C 3%). 
The administration of PD plus PZP in the morning pre- 
vented the inhibitory effect of PD on ACTH secretion, re- 
sulting in a secretory pattern identical to that found when 
subjects were pretreated with placebo (Fig. 1). Thus, ACTH 
total AUC values were reduced by only 6 t 1.3% with respect 
to those after placebo treatment. In contrast, pretreatment 
with both drugs in the evening did not modify the decreasing 
effect on ACTH levels induced by exclusive I’D administra- 
tion. In fact, total AUC values (Table 1) and integrated ACTH 
levels corresponding to partial time intervals were similar 
under both sets of conditions (Fig. 1). The percent reduction 
in ACTH total AUC with respect to that during the placebo 
test was identical to that calculated after exclusive I’D treat- 
ment (38.1 & 5.6%). However, the ACTH area corresponding 
to the initial interval after I’D plus PZP was slightly lower 
than that measured after exclusive administration of I’D (6.7 
-t 1.1 DS. 8.1 -C 1.4 pmol/L*30 min; P = NS; Fig. 1). Conse- 
quently, the combined treatment with I’D and PZP induced 
an amplification of circadian ACTH variation (62.6 i 5.5%; 
P < 0.05 us. placebo). 
Cortisol 
Morning basal cortisol levels after placebo treatment were 
maximal at 0800 h (516.9 i 33.9 nmol/L) and declined pro- 
gressively throughout the sampling period (nadir, 1015 h; 
264.1 t 26 nmol/L; Fig. 2). According to the circadian vari- 
ation displayed by ACTH values, cortisol concentrations 
were significantly lower in the evening, as demonstrated by 
the comparison between total AUC values (Table 1). Pre- 
treatment with PD did not induce any change in the cortisol 
secretory pattern in either the morning or the evening despite 
the reduction in ACTH concentrations induced by the cho- 
linergic agonist in both situations. Combined administration 
of PD and PZP led to a significant reduction in evening 
cortisol levels compared to values after either placebo or PD 
treatment, whereas the same treatment was devoid of any 
effect when given in the morning (Fig. 2). The percent vari- 
ation in nocturnal cortisol levels with respect to morning 
values was similar when subjects received placebo, I’D, or the 
combination of PD and PZP (71.4 -C 5.3%, 75.2 2 4.4%, and 
82.1 t l%, respectively). 
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FIG. 1. Mean values and Dartial inte- 
grated areas of secretion of’ACTH after 
placebo (open circles and open bars), PD 
(closed circles and black bars), and PD 
plus PZP (closed squares and dashed 
bars) administration. Top panel, Morn- 
ing studies. Bottom panel, Evening 
studies. *, P < 0.05; **, P < 0.01. 
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TABLE 1. Total AUC values of ACTH, cortisol, and GH after 
placebo, PD, and PD plus PZP in the morning and evening 
Placebo PD PD + PZP 
ACTH 
Morning 103.1 i- 16.9 74 2 11.9” 96.8 k 21 
Evening 53.8 i 7.gh 34.3 t 5.5"J 34.2 -t 6.2"," 
Cortisol 
Morning 6876 I 479 7254 5 809 7137 k 442 
Evening 1895 i 326* 1725 2 320” 1277 i- 113h 
- GH 
Morning 2.7 -t 0.9 45.2 i 13.7" 7.57 t 3.2" 
Evening 76.3 -+ 33.7' 130.4 k 24.3' 32.3 2 19.1b 
Values shown are the mean i SEM. 
0 Significantly different from placebo values (P < 0.05). 
’ Significantly different from morning values (P < 0.05). 
GH Discussion 
Morning GH levels after placebo treatment were near the 
lower detection limit of the assay, remaining unchanged over 
the duration of the study. Evening GH concentrations were 
higher than morning levels, as assessed by total AUC values 
(Table 1). As expected, I’D administration elicited a clear GH 
Although animal experiments have provided data sup- 
porting a positive influence of cholinergic pathways on the 
HPA axis, studies on the effect of cholinergic agents on 
ACTH release in man have produced conflicting results. 
Investigations carried out by Risch et al. (6, 7) and Lewis et 
(Y) 00 MI xl 0, 00 (II 31) 23(XL2330 2130.00.30 0030.0130 
Time (h) Time intervals (h) 
response in the morning as well as the evening (mean GH 
peak, 4.1 -C 1.2 and 10.2 -C 1.6 ng/mL, respectively). Thus, 
GH AUC values after I’D treatment were superior to those 
found after placebo treatment at both times of the day (Table 
l), confirming that cholinergic stimulation was taking place. 
The percent GH stimulation over basal values after PD treat- 
ment was higher in the morning (1574 + 214% vs. 70.9 5 
15%). The addition of PZP to PD led to a marked reduction 
of the GH response to I’D in the morning (GH peak, 0.73 t- 
0.4 vs. 4.1 -C 1.2 ng/mL; P < 0.01) as well as in the evening 
(3.66 t 2.34 ‘us. 10.2 t 1.6 ng/mL; P < 0.05). Estimations of 
GH total AUC values also suggested that cholinergic GH 
stimulation was significantly attenuated when both drugs 
were given (Table 1). 
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FIG. 2. Mean values and partial inte- 
grated areas of secretion of cortisol after 
placebo (open circles and open bars), PD 
(closed circles and black bars), and PD 
plus PZP (closed squares and dashed 
bars) administration. Top panel, Morn- 
ing studies. Bottom panel, Evening 
studies. ‘I’, P < 0.05; **, P < 0.01. 
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al. (14) showed that physostigmine administration to normal 
volunteers increased basal ACTH and cortisol levels. On the 
contrary, other researchers (8-10) failed to demonstrate a 
significant variation in ACTH or cortisol concentrations after 
treatment with anticholinesterase agents. More recently, new 
data have been presented showing that I’D or physostigmine 
increases the pituitary-adrenal responses to CRH (11) and 
meal intake (15) in normal individuals, which argues in favor 
of a stimulatory influence exerted by the cholinergic system 
on HPA function in these conditions. 
Our results show that nonspecific cholinergic activation by 
PD inhibits spontaneous ACTH secretion during both the 
morning and evening periods. Some methodological factors 
may help to explain the apparent discrepancies between 
previous studies and our results. In contrast to other reports, 
normal function of the HPA axis was documented in our 
group of volunteers, who exhibited a normal circadian vari- 
ation of ACTH and cortisol levels after placebo administra- 
tion. On the other hand, side-effects induced by the admin- 
(IX ,I0 ox.30 ox 30 09 30 ffl30 IO 30 






q PD + PZP 
13 (Xl 2.1 30 23 30 Ml30 00 30 01 30 
Time intervals (h) 
istration of high doses of physostigmine, such as those used 
by Risch ef al. (6, 7) and Lewis et al. (14), led to a classic 
symptomatic and hormonal stress responses, with partici- 
pation of PRL, cortisol, and ACTH (12). Both the simulta- 
neous rise in PRL and the prevention of cortisol and ACTH 
responses by pretreatment with the peripheral cholinergic 
antagonist glycopyrrolate (14) support the hypothesis that 
physostigmine-induced HPA axis stimulation is mediated by 
mechanisms independent of specific cholinergic activation. 
Our data do not agree with those reported by Freeman et al. 
(8), who did not find any change in ACTH levels after the 
administration of I’D to normal subjects in the morning. One 
possible explanation is that stressful effects due to I’D ad- 
ministration could lead to HPA axis activation in some in- 
dividuals, thus contributing to mask the real cholinergic 
effect on morning ACTH secretion just when the inhibitory 
effect of I’D on ACTH secretion seems to be weaker. The 
stimulation of cortisol and P-endorphin secretion induced by 
low doses of physostigmine in old men could be due to 
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disturbances in the cholinergic system related to aging (10). 
The impairment of GH responses to the cholinergic agonist 
exhibited by the same individuals supports that hypothesis. 
Our study demonstrates that the ACTH inhibition induced 
by PD administration in the morning is completely abolished 
by the addition of PZP, suggesting that the reduction in 
ACTH concentrations observed at that time of day requires 
the participation of Ml muscarinic receptors. Stimulation of 
GH secretion by I’D and its inhibition by concurrent PZP 
treatment support the view that cholinergic tone manipula- 
tion was, in fact, taking place as expected. Finally, the in- 
hibitory effect of I’D on ACTH secretion cannot be ascribed 
to stress, a condition that promotes ACTH and cortisol re- 
lease. There is a genuine possibility that doses of I’D superior 
to those given in this study have a different effect on ACTH 
secretion. However, this is unlikely because administration 
of doses higher than 120 mg has been reported to cause 
similar GH release (16). In addition, high doses of I’D may 
produce significant side-effects and stress system activation, 
leading to HPA axis stimulation by noncholinergic 
mechanisms. 
Our data agree with those reported by Evans et al. (17), 
who showed that iv administration of atropine in the morn- 
ing increased the ACTH and P-endorphin responses to in- 
sulin-induced hypoglycemia in normal subjects, attributing 
to cholinergic muscarinic receptors an inhibitory influence 
on stimulated ACTH secretion. Unfortunately, no informa- 
tion was available on the effect of muscarinic receptor block- 
ade on spontaneous HPA activity in this study. 
To date, no studies have been conducted to investigate the 
effect of cholinergic stimulation on nocturnal HPA activity. 
Our data show that the inhibitory effect of I’D on ACTH 
secretion is also operative at night, despite the fact that ab- 
solute concentrations and pulsatility of ACTH secretion dif- 
fer from those observed during the morning period. ACTH 
inhibition during the initial and middle phases of the sam- 
pling period was greater in the evening as was the overall 
suppression of ACTH levels compared to those found in the 
morning, suggesting that corticotroph sensitivity to the in- 
hibitory effect of PD is higher during the nocturnal period. 
However, the addition of PZP does not reverse the PD- 
induced reduction of ACTH secretion, suggesting that Ml 
muscarinic receptors are not involved in the nocturnal effect 
of I’D on ACTH secretion. Thus, in contrast to results ob- 
tained in morning experiments, the association of I’D and 
PZP led to a decrease in ACTH levels comparable to that seen 
after PD alone. These results are consistent with the partic- 
ipation of cholinergic receptors different from those of the 
Ml type in the nocturnal effect of PD on ACTH levels, raising 
the possibility that modulation of ACTH secretion by the 
cholinergic system involves a different type of receptor de- 
pending on the time of the day. 
PD administration induced a substantial GH response 
during both study periods as a consequence of somatostatin 
inhibition (18), thus corroborating an effective stimulation of 
cholinergic tone. Relative GH increase after pretreatment 
with PD in the morning was greater than that found in the 
evening, suggesting a low somatostatinergic tone during the 
nocturnal period, as previously proposed (19). This circadian 
variation in the GH response to PD is not paralleled by that 
of ACTH, which suggests that the mechanisms mediating 
GH stimulation after cholinergic agonist administration may 
be different from those involved in ACTH suppression, as 
has been suggested in elderly people (10). 
Regarding the mechanisms by which PD inhibits ACTH 
secretion, a suprapituitary site of action should be consid- 
ered, as there is no proof of the existence of cholinergic 
receptors on corticotroph cells, and according to this, addi- 
tion of the cholinergic agonist arecoline to dispersed anterior 
pituitary cells in culture does not have any effect on ACTH 
secretion (5). The fact that PZP, due to its hydrophilic prop- 
erties, does not penetrate the blood-brain barrier to a great 
extent (20) points to the median eminence as the most likely 
site of action for this drug to antagonize the effects of PD on 
ACTH release. However, effects on other hypothalamic 
structures leading to changes in CRH or AVP secretion can- 
not be ruled out, as experimental evidence suggests that 
cholinergic pathways have a significant influence on the 
synthesis of both peptides (21, 22). 
Interestingly, cortisol levels remained unchanged despite 
the fact that ACTH concentrations were reduced after pre- 
treatment with PD. This suggests that the sensitivity of ad- 
renal glands to small changes in ACTH levels is not enough 
to induce significant variations in cortisol concentrations. 
Alternatively, the sampling period might be too short to 
detect a reduction of cortisol concentrations that may occur 
later. Furthermore, a direct adrenal effect of cholinergic 
drugs cannot be ruled out. In this context, a stimulatory effect 
of acetylcholine infusions on adrenal cortisol output in hy- 
pophysectomized animals has been described (23). Thus, PD 
administration may counteract the effects of ACTH reduc- 
tion by promoting direct adrenal cortisol release. These re- 
sults are in agreement with other studies (B-10) that failed 
to find any cortisol variation when giving PD to normal 
subjects in the morning, and with that of Evans et al. (17), who 
observed no changes in hypoglycemia-stimulated cortisol 
levels after atropine administration to normal individuals 
despite achieving a significant rise in ACTH concentrations. 
The addition of PZP induced a significant decrease in cortisol 
values in the initial phase of the nocturnal test, just when 
maximum ACTH suppression was attained. A superior re- 
duction of ACTH levels in the early part of the experiment 
or a direct effect of PZP on adrenal cortisol release represent 
possible mechanisms to explain the different cortisol patterns 
seen after the administration of PD and PZP. It seems that 
both factors, a decrease in ACTH levels and simultaneous 
administration of PZP, are required to induce a significant 
reduction in cortisol levels. Taken together, these data indi- 
cate that estimation of cortisol levels is not a reliable index 
to assess the effects of cholinergic manipulation on cortico- 
troph cell function. 
When assessing the relationship between diurnal and noc- 
turnal HPA activities, it becomes evident that the percent 
variation in ACTH or cortisol observed after placebo admin- 
istration remained constant after pretreatment with PD. 
However, the differences seen in the cortisol and ACTH 
responses to combined PD and PZP treatment at both times 
of the day give support to the possibility of a modulatory 
influence of cholinergic tone on the circadian rhythm of the 
HPA axis. 
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In summary, this study reveals that, in contrast to exper- 
imental animals, cholinergic activation by PD inhibits ACTH 
secretion in man, suggesting the involvement of a different 
type of cholinergic receptors depending on the time of day 
at which the test is carried out. This functional relationship 
between the cholinergic system and the HPA axis provides 
further insight into the regulation of HPA function and opens 
new perspectives in the pathophysiology of behavior disor- 
ders and stress conditions. 
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